Table 2. Summary of hematologic and... | American Society of Hematology

Table 2.

Summary of hematologic and cytogenetic responses to TKI in advanced phase CML^*

	CHR		CCyR		MMR	OS
	AP	BP	AP	BP	AP	AP	BP
Imatinib	70%- > 90%	11%-35%	16%-60%	0%-10%	19%-63%	50%-60% at 5 years	7-10 months^†
Nilotinib (de novo)	>90%	—	80%-90%	—	70%	90% at 3 years
Nilotinib (progressed)	22%-46%	21%-42%^‡	0%-21%	14%-38%^§	10%	60%-70% at 2 years	32% at 2 years
Dasatinib (de novo)	>90%	—	80%-90%	—	70%	90% at 3 years
Dasatinib (progressed)	45%-52%	28%-61%^‡	18%-33%	27%-35%^§	10%	60%-70% at 2 years	30% at 2 years
Bosutinib (progressed)	57%^‡	28%^‡	40%^§	50%^§	11%	60% at 4 years	17% at 4 years
Ponatinib (progressed)	55%^‡	32%^‡	24%	18%^§	34%	84% at 1 year	29% at 1 year

	CHR		CCyR		MMR	OS
	AP	BP	AP	BP	AP	AP	BP
Imatinib	70%- > 90%	11%-35%	16%-60%	0%-10%	19%-63%	50%-60% at 5 years	7-10 months^†
Nilotinib (de novo)	>90%	—	80%-90%	—	70%	90% at 3 years
Nilotinib (progressed)	22%-46%	21%-42%^‡	0%-21%	14%-38%^§	10%	60%-70% at 2 years	32% at 2 years
Dasatinib (de novo)	>90%	—	80%-90%	—	70%	90% at 3 years
Dasatinib (progressed)	45%-52%	28%-61%^‡	18%-33%	27%-35%^§	10%	60%-70% at 2 years	30% at 2 years
Bosutinib (progressed)	57%^‡	28%^‡	40%^§	50%^§	11%	60% at 4 years	17% at 4 years
Ponatinib (progressed)	55%^‡	32%^‡	24%	18%^§	34%	84% at 1 year	29% at 1 year

^*

Adapted from Bonifacio et al.¹⁰

Median OS.

Hematologic response.

Major cytogenetic response.